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Abstract
p53, a strong tumor suppressor protein, is known to be involved in cellular senescence, particularly premature cellular
senescence. Oncogenic stresses, such as Ras activation, can initiate p53-mediated senescence, whereas activation
of the Ras-mitogen-activated protein kinase (MAPK) pathway can promote cell proliferation. These conflicting facts
imply that there is a regulatory mechanism for balancing p53 and Ras-MAPK signaling. To address this, we evaluated
the effects of p53 on the extracellular signal-regulated kinase (ERK) activation and found that p53 could suppress ERK
activation through de novo synthesis. Through several molecular biologic analyses, we found that RKIP, an inhibitor of
Raf kinase, is responsible for p53-mediated ERK suppression and senescence. Overexpression of RKIP can induce
cellular senescence in several types of cell lines, including p53-deficient cells, whereas the elimination of RKIP by
siRNA or forced expression of ERK blocks p53-mediated cellular senescence. These results suggested that RKIP is
an essential protein for cellular senescence. Moreover, modification of the p53 serine 46 residue was critical for RKIP
induction and ERK suppression as well as cellular senescence. These results indicated that RKIP is a novel p53 target
gene that is responsible for p53-mediated cellular senescence and tumor suppressor protein expression.
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Introduction
Senescence is one of the cell’s responses to damage. It is induced by
various stresses such as replicative stress, oncogene activation, telomere
dysfunction, and DNA damage [1–6]. In addition, cellular senes-
cence is considered as an initial barrier to tumor formation. Indeed,
during the tumorigenesis, a large portion of adenoma is regressed by
senescence [6,7].
The molecular mechanism behind cellular senescence has not been
fully demonstrated until now. According to previous reports, p53 and
p16/Rb pathways are known to be involved in senescence [8]. Induc-
tion of p16 and p53 has been observed in murine senescent tissues
[6,7,9–11]. In addition, p53 is a well-defined tumor suppressor gene
that can induce apoptosis, cell cycle arrest, as well as senescence [12].
The main role of p53 is a transcriptional factor that binds to the pro-
moter regions of target genes (including p21, PUMA, BAX, PAI-1,
etc.) to enhance their expression. In contrast, p53 expression is tightly
regulated by posttranscriptional modifications, which are phosphoryla-
tion, acetylation, methylation, ubiquitylation, and sumoylation [13].
Among them, phosphorylation of p53 by several kinases (such as
ATM, Chk1/2, and HIPK) on distinct sites following stresses such as
DNA damage or oncogene activation is essential for regulation of
p53 expression. Although significant increases of p53 have not been
observed during the normal aging process, transgenic mice exhibiting
either a truncated form of p53 with mutations in the MDM2-binding
domain or a constitutive p53 C-terminal region that escapes MDM2
binding show an aged phenotype [14,15]. Another transgenic mouse
exhibiting a BRCA1 mutation also displays this aged phenotype due
to p53 activation in response to endogenous DNA damage [16]. How-
ever, simple overexpression of p53 or an elevated expression of p53 due
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to a deletion of MDM2 cannot induce senescence [17,18], suggesting
that p53-induced senescence only occurs under abnormal condition.
Oncogene activation can induce cell cycle promotion as well as
p53-dependent senescence [19–21]. Until now, how these opposite
events could have occurred by oncogene activation has not been fully
demonstrated. According to a recent report, a negative feedback loop
induced by Ras-Raf-extracellular signal-regulated kinase (ERK) leads to
Ras-mediated senescence [22]. Considering the fact that oncogenic
Ras-induced senescence is fully dependent on p53 [20,23,24], nega-
tive feedback loop would be related with p53 function. Thus, we
propose the following hypothesis: Cellular senescence is achieved by
p53-mediated Ras-mitogen-activated protein kinase (MAPK) signaling
suppression. To address this hypothesis, we examined the effect of p53
on MAPK kinase signaling and found that the Raf kinase inhibitor
RKIP is a new target gene of p53. Overexpression or induction of
RKIP, which can follow DNA damage or oncogene-induced p53 acti-
vation, evokes cellular senescence, whereas RKIP suppression through
siRNA can inhibit cellular senescence. Moreover, induction of RKIP
and subsequent cellular senescence is dependent on modification
of the p53 serine 46 (S46) residue. Considering the frequent reduced
levels of RKIP observed in human cancer tissues, RKIP potentially
works as a tumor suppressor linked to induction of cellular senescence.
Materials and Methods
Cell Lines and Regents
A549, MKN45, MKN74, and PC3 were obtained from ATCC
(Rockville, MD), and HCT116 cell lines were kindly provided by
B. Vogelstein and K. Kinzler (The Swim Across America Laboratory
at Johns Hopkins and the Howard Hughes Medical Institute at Johns
Hopkins Kimmel Cancer Center, Baltimore, MD). Cell lines were
cultured in RPMI 1640 (Thermo Scientific, Rockford, IL) with 10%
FBS (Thermo Scientific) and 1% antibiotics (Thermo Scientific).
Mouse embryonic fibroblast (MEF) cells were cultured in Dulbecco’s
modified Eagle’s medium (Thermo Scientific) supplemented with 10%
FBS (Thermo Scientific) and 1% antibiotics (Thermo Scientific). All
cell lines were maintained in humidified incubator at 37°C with 5%
CO2. Adriamycin (Adr), etoposide (Etop), hydroxyurea, and IGF-1 were
obtained from Sigma (St Louis, MO). Raf kinase inhibitor 1 was ob-
tained from Calbiochem (Merck, Darmstadt, Germany). For Western
blot analysis and immunofluorescence staining, anti–phospho-p53
(S15, S46 and S392), anti–phospho-ERK, and RKIP were purchased
from Cell Signaling Technology (Danvers, MA). Antibodies against
DcR2, p53 (DO-1), and actin were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA).
Vectors and Transfection
pCMV-RKIP-HAwas provided byG. Keum (DavidGeffen School of
Medicine at University of California, Los Angeles, CA), and p53K302R
and p53K382R [25] were obtained from P. P. Pandofi (Harvard Univer-
sity, Boston,MA). p53 S46A and S46Dwere provided by D. B. Donner
(University of California, San Francisco, CA) [26]. Si-p53 was provided
by L. D.Mayo (Herman B.Wells Center for Pediatric Research, Indiana
University School of Medicine, Indianapolis, IN). The pcDNA-ERK
expression vector was obtained from D. S. Min (Pusan National Uni-
versity, Busan, Korea). For transfections, we used the jetPEI trans-
fection agent (Polyplus Transfection, New York, NY) following the
manufacturer’s protocol. The vector (1.5 μg) was mixed with 1.5 μl of
jetPEI reagent in 150 mM NaCl solution. After incubation for 15 min-
utes at room temperature, the mixture was added to the cell. After
3 hours, the serum-free medium was replaced with 10% FBS–containing
medium. The si-RKIP oligomer directed against RKIP, which has
previously been used for RKIP suppression [27], was provided by
Cosmogenetech (Seoul, Korea). For RKIP suppression, we generated
si-RKIP, CACCAGCATTTCGTGGGATGGTCTTTCAAGAG-
AAGACCATCCCACGAAATGCTGGTG and si-control (Si-C),
GCGCGCTTTGTAGGATTCGTTTTCAAGAGAAACGAATCC-
TACAAAGCGCGC.
Western Blot Analysis
Cells, transfected or treated with chemicals, were lysed with RIPA
(containing a protease inhibitor cocktail) and were centrifuged at
14,000 rpm for 30 minutes. Twenty micrograms of cell extracts was
separated by sodium dodecyl sulfate–polyacrylamide gel electrophoresis
and transferred onto a polyvinylidene difluoride (PVDF) membrane
(Millipore, Billerica, MA). Blots were blocked in TBS buffer containing
0.05% Tween 20 and 3% nonfat dry milk for 1 hour at room tem-
perature. The membrane was incubated 1 hour to overnight at 4°C
with an appropriated primary antibody, followed by reaction with a
secondary antibody at room temperature for 1 hour. The proteins were
visualized using West-zol (Intron, Seoul, Korea) as recommended by
the manufacturer.
Immunofluorescence Staining
After being seeded on cover glasses, cells were transfected with
indicated vectors or treated with chemicals. After fixing with meth-
anol for 10 minutes at 4°C, cells were incubated with blocking buffer
[phosphate-buffered saline (PBS) + anti-human Ab (1:500)] for 1 hour.
After washing with PBS twice, cells were incubated with anti–phospho-
ERK and anti-DcR2 in blocking buffer (1:200) for 2 hours and
sequentially with anti-mouse Ab–fluorescein isothiocyanate or anti-
rabbit Ab–fluorescein isothiocyanate in blocking buffer (1:1000) for
2 hours and mounted. Nucleus was stained with 4′,6-diamidino-2-
phenylindole (DAPI). Immunofluorescence signal was detected through
fluorescence microscopy (Zeiss, Oberkochen, Germany).
Staining of Senescence-Associated β-Galactosidase Activity
For senescence-associated β-galactosidase activity staining (SA-β-Gal
staining), cells were incubated with indicated chemicals or transfected
with indicated vectors for 24 hours. After washing with serum-free me-
dium, cells were incubated for an additional 24 hours in serum-free
medium. The cells were then washed with PBS (pH 7.2) and fixed. After
washing, cells were stained in X-gal staining solution. All reagents were
supplied by the SA-β-Gal Staining Kit (Cell Signaling Technology).
RNA Isolation and Reverse Transcription–Polymerase
Chain Reaction
For mRNA analysis, we isolated total RNA using an RNeasy Mini
Kit (Qiagen, Germantown, MD), and 1 μg of RNA was converted
into cDNA using MMLV RT (Invitrogen, Carlsbad, CA) and random
hexamer. After dilution, we used the cDNA for subsequent polymerase
chain reactions (PCRs) using i-start Taq (Intron). The PCR conditions
included a denaturing step at 95°C for 5 minutes, followed by 34
cycles of denaturation at 95°C for 1 minute, annealing at 60°C for
1 minute, and elongation at 72°C for 1 minute. Reverse transcription
(RT)–PCR was performed with specific primers of target genes. The
primers used in this study were given as follows: RKIP (forward),
5′-ATGCCGGTGGACCTCAGCAAGT-3′; RKIP (reverse),
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5′-CTTCCCAGACAGCTGCTCGTAC-3′; dual-specific phosphatase
14 (DUSP14; forward), 5′-ATGAGCTCCAGAGGTCACAGC-3′;
DUSP14 (reverse), 5′-TCCCCCAGTAAGGCATCAGGT-3′;
p21 (forward), 5′-CGTGAGCGATGGAACTTCGAC-3′; p21
(reverse), 5′-GATGTAGAGCGGGCCTTTGAG-3′; glyceraldehyde
3-phosphate dehydrogenase (GAPDH) (forward), 5′-ATCTTCCAG-
GAGCGAGATCCC-3′; GAPDH (reverse), 5′-AGTGAGCTTCCC-
GTTCAGCTC-3′.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide Assay and Cell Proliferation Analysis
To measure the cell viability, cells were transfected with indicated
vectors for 72 hours. For 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay, cells were incubated with 0.5 mg/
ml MTT solution (Calbiochem) for 4 hours at 37°C. After removing
excess solution, the precipitated materials were dissolved in 200 μl
of DMSO and quantified by measuring absorbance at 540 nm.
For cell proliferation analysis, after removing the medium, cells were
stained with trypan blue solution (Gibco, Darmstadt, Germany) for
10 minutes at room temperature.
Chromatin Immunoprecipitation
Cells treated with Adr, Etop, or hydroxyurea for 2 hours were fixed
with 1% paraformaldehyde for 0.5 hour. After washing, the cells
were sonicated. After pre-clearing with normal IgG, the lysates were
incubated with p53 (DO-1) antibody and protein A/G agarose bead
(Invitrogen) for 1.5 hours at each step. The cells were collected by
centrifugation and washed twice with PBS, after which precipitated
DNA-protein complexes were incubated in DNA extract buffer con-
taining protease A for 2 hours at 50°C. Next, we added equal volumes
of phenol/chloroform/isoamyl alcohol (25/24/1) solution and isolated
the DNA. After washing with alcohol, we used the isolated DNA as
our PCR template. The primers used in this study were given as fol-
lows: RKIP-1 (forward), 5′-ATCTTCCTGCTTTGGCCTCCC-3′;
RKIP-1 (reverse), 5′-CTGCCGAGTTCTCGGGAACAG-3′; RKIP-2
(forward), 5′-ATCTTCCTGCTTTGGCCTCCC-3′; RKIP-2
(reverse), 5′-CTCGACACACGCAGGCTGAAC-3′; DUSP14-1 (for-
ward), 5′-ACTGCTCAGCAATTCTGAGGC-3′; DUSP14-1 (re-
verse), 5′-GGGCATTTGAGGGCTCATTTC-3′; DUSP14-2
(forward), 5′-ACCTGTTCCAGCAAGCGTCAG-3′; DUSP14-2
(reverse), 5′-GTCTCTTACCCTGCCTCACAC-3′; DUSP5
(forward), 5′-AGTGAGCTTGGGGGCAGAAAC-3′; DUSP5
(reverse), 5′-GAGGAGCTGTTTTCTGGTCCC-3′; p21-1 (forward),
5′-CTCATGAGGACTCAGCAGAGC-3′ ; p21-1 (reverse),
5′-ACATCCTGCCAGGCACATCAG-3′; p21-2 (forward), 5′-
CTTAACCACCAGGATACAGCC-3′; p21-2 (reverse), 5′-
ACAGTCTGACAGTTCCTCCAG-3′.
Results
DNA Damage Induces Cellular Senescence
To determine whether the Ras-MAPK pathway plays a role in p53-
dependent cellular senescence, we treated the p53-positive human
A549 lung cancer cell line with a DNA-damaging agent. Because the
A549 cell line harbors endogenous oncogenic K-Ras and wild-type
p53, cellular senescence is triggered by Adr, which is a topoisomerase II
inhibitor as well as a DNA-intercalating agent [28–31]. Adr treatment
decreased p-ERK expression, whereas p53 expression was increased
(Figure 1A). To verify that the reduced p-ERK expression observed
was a common response to DNA-damaging agents, we examined the
effect of another topoisomerase II inhibitor, Etop, on ERK activation.
In previous studies, Adr and Etop have shown mutually incompatible
effects on p-ERK expression [32]. Indeed, contrary to the effects of
Adr treatment, p-ERK expression increased in response to Etop treat-
ment (Figure 1B). According to a previous study, DNA strand breakages
lead to apoptosis and cell cycle arrest, whereas senescence results from
DNA damage such as DNA alkylation or intercalation [2]. To compare
the senescence-promoting ability of the two chemicals, we performed
SA-β-Gal staining. Adr but not Etop induced cellular senescence (Fig-
ure 1, C–E). Because p16/INK and DcR2 are commonly used senes-
cence markers [7,33–35], we checked the expression of DcR2 and
found that Adr treatment increased levels of DcR2 (Figure 1, F and
G). As the A549 cell line is p16/p14 negative, these results suggested
that Adr induced cellular senescence in a p16/Rb-independent manner.
Suppression of p-ERK Is a p53-Dependent Event
To verify that p-ERK reduction is achieved in a p53-dependent
manner, we checked the reduction of p-ERK by Adr-treatment in
HCT116 p53 isogenic cell lines [36]. In contrast to reduction of
p-ERK and increase of SA-β-Gal–positive cells in response to Adrin
p53-positive cell lines, p53-null cells (HCT116 p53−/−) did not show
the reduction of p-ERK and senescence (Figure 2, A and B). However,
reconstruction of p53 in HCT 116 p53−/− cells by transfection of
wild-type p53 could restore the Adr-induced senescence (Figure 2C).
These results suggest that Adr induced senescence and p-ERK suppres-
sion is achieved in a p53-dependent manner.
RKIP Is Induced by Adr but Not Etop
Because the major function of p53 is transcriptional factor [37,38],
we checked the involvement of transcriptional activity of p53 on
p-ERK inhibition. Blocking the de novo synthesis of p53 by cyclo-
hexamide treatment could block the p-ERK suppression (Figure W1A).
We next measured the RNA expression of several Ras-Raf-MAPK
inhibitors, including DUSP14, DUSP5, and RKIP. Indeed, DUSP14
and DUSP5 have been revealed as p53 target genes [39,40], and RKIP
is known to be an inhibitor of Raf-MAPK [41]. The transcripts of
DUSP14 and RKIP were increased by Adr treatment (Figure 2D).
Since DUSP5 expression was not altered by Adr treatment (data not
shown), we excluded it from our further analyses. In addition, RKIP
responded more specifically to Adr treatment than to Etop treatment,
whereas DUSP14 expression did not show obvious difference be-
tween Adr- and Etop-treated cells (data not shown). Indeed, RKIP
expression at translation level was obviously induced by Adr treatment
in a time- and dose-dependent manner (Figure 2, E and F). In contrast,
Etop did not induce RKIP at the similar condition (Figure 2, E andG).
Moreover, DcR2 was increased along with RKIP expression (Fig-
ure 2F ), suggesting that RKIP was a mediator of cellular senescence.
To confirm this result, we treated Adr on the human gastric cancer cell
line MKN45, which harbors wild-type p53 and wild-type K-Ras. As
we expected, Adr treatment induced the RKIP expression along with
suppression of p-ERK (Figure W1B). These results implicate that
RKIP is a major candidate for reducing p-ERK expression and inducing
cellular senescence in response to Adr treatment.
RKIP Is a Direct Target Gene of p53
Previously, we showed that reduction of p-ERK showed the
dependence with p53 (Figure 2A), and RKIP was induced by Adr
(Figure 2D). Thus, we checked the relevance between p53 and RKIP
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induction. First of all, we measured the expression of RKIP in Adr-
treated HCT116 p53 isogenic cell lines and found that induction of
RKIP at transcription and translation levels was fully dependent on
p53 status (Figures 3A and W1C ). To confirm this, we transfected
p53 into p53-null HCT116 cells and measured the expression of RKIP.
Overexpression of wild-type p53 could induce the RKIP expression
(Figures 3B and W1D). However, ectopic expression of a mutant form
of p53 (R175H) did not induce RKIP (Figures 3B and W1D). More-
over, p53 knockdown diminished Adr-induced RKIP expression
(Figure 3C ). These results indicated that RKIP induction was fully
Figure 1. Adr induced p-ERK suppression and senescence. (A) Western blot analysis of A549 cells showed that p-ERK was reduced after
treatment with Adr (2 μg/ml) for the indicated amount of time. Actin was shown as a loading control. (B) Western blot analysis of A549 cells
showed that p-ERK was induced after treatment with Etop (5 μM) for the indicated amount of time. Actin was shown as a loading control.
(C) SA-β-Gal staining of A549 cells showed that Adr but not Etop induced cellular senescence. A549 cells were incubated with Adr (2 μg/ml)
or Etop (5 μM) for 24 hours in serum-free media. After fixing, cells were stained with SA-β-Gal staining solution. (D) Photograph of SA-β-Gal
staining well. (E) Quantification of SA-β-Gal–positive cells. At least 200 cells were counted from three independent experiments, and the
mean results are represented as a bar graph. (F) Western blot analysis of A549 cells showed that DcR2 was increased by Adr treatment.
Cells were incubated with the indicated concentrated chemicals for 4 hours. (G) Immunostaining of A549 cells showed the effect of Adr
or Etop on DcR2 and p-ERK. After treatment with Adr (2 μg/ml) or Etop (5 μM) for 4 hours, cells were fixed and stained with anti-DcR2 and
anti–p-ERK. Nucleus was stained with DAPI.
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dependent on p53. To verify that RKIP is direct target of p53, we
searched the RKIP promoter region and found two putative p53 con-
sensus binding sequence (CBS; Figure W2). To determine whether
these sites were occupied by p53, we performed chromatin immuno-
precipitation (ChIP) assay in RKIP promoter, comparing with the p21
and DUSP14-2 promoters as positive controls and GAPDH, DUSP5,
and DUSP14-1 as negative controls. Of the two p53 CBS in the
RKIP promoter region, the second CBS was amplified by ChIP PCR
Figure 2. RKIP is induced by Adr but not Etop. (A) Western blot analysis of HCT116 isogenic cells showed that p-ERK was decreased
in p53-positive (HCT116 p53+/−) cells but not in p53-deficient (HCT116 p53−/−) cells after treatment with Adr (2 μg/ml) for the indicated
amount of time. Actin was shown as a loading control. (B) SA-β-Gal staining of HCT116 isogenic cells showed that Adr induced cellular
senescence in HCT116 p53+/− cells but not in HCT116 p53−/− cells. Etop did not induce cellular senescence in both cell lines. Cells
were incubated with Adr (2 μg/ml) or Etop (5 μM) for 24 hours and subjected to SA-β-Gal staining. (C) SA-β-Gal staining of HCT116 p53−/−
cells showed that Adr induced cellular senescence in the presence of p53. Cells were transfected with wild-type p53 for 24 hours and
incubated with 1 μg/ml Adr for 24 hours. After fixing, cells were stained with SA-β-Gal staining solution. (D) RT-PCR analysis of A549 cells
showed that transcripts of RKIP and DUSP14 were increased in treatment with Adr (2 μg/ml) for the indicated amount of time. p21 was
used as a positive control, and GAPDH was used as the loading control. (E) Western blot analysis of A549 cells showed that RKIP was
induced after treatment with Adr. Cells were incubatedwith Adr (2 μg/ml) or Etop (5 μM) for the indicated amount of time. Actinwas shown
as a loading control. (F) Western blot analysis of A549 cells showed that RKIP and DcR2 were increased after treatment with Adr for the
indicated time and concentration. Actin was shown as a loading control. (G) Western blot analysis of A549 cells showed that RKIP and
DcR2 were not altered after treatment with Etop for the indicated time and concentration. Actin was shown as a loading control.
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in Adr-treated cells (Figure 3D). On the basis of these results, we
suggested that RKIP was a direct p53 target gene.
RKIP Is Also Induced by Oncogene Activation or Growth
Factor Stimulation
To verify that RKIP induction is common to p53-dependent cel-
lular senescence, we examined RKIP expression under growth factor–
and oncogene-induced senescent cells. Insulin-like growth factor 1
(IGF-1)–induced senescence is also mediated by the p53 pathway
[15,42], and oncogenic Ras-induced senescence is fully dependent on
p53 status [20,21]. Indeed, RKIP expression was induced in IGF-1–
stimulated senescent A549 cells (Figure 3, E and F ). Moreover, the
induction of RKIP and DcR2, in response to IGF-1, was only observed
in HCT 116 p53+/− cells but not in HCT 116 p53−/− cells (Fig-
ure 3G ). In addition, oncogenic Ras could induce RKIP expression
in a p53-dependent manner (Figure 3H ).
RKIP Induces Senescence through ERK Suppression
To determine whether RKIP induction is required for Adr-induced
senescence, we performed the RKIP knockdown experiment using
Figure 3. RKIP is a direct target of p53. (A)Western blot analysis of HCT116 p53 isogenic cell lines showed that RKIP was induced in HCT116
p53+/− cells after treatment with Adr (2 μg/ml) for the indicated time. Actin was shown as a loading control. (B) Western blot analysis of
HCT116 p53−/− cells showed that RKIP was induced in the presence of wild-type p53. Cells were transfected with wild-type or transcrip-
tional activity–deficient mutant p53 and treated with Adr (2 μg/ml) for 4 hours. (C) Western blot analysis of HCT116 p53+/− cells showed
that RKIP was not induced after the treatment with Adr following the elimination of p53. Cells were transfected with siRNA against p53 for
24 hours and incubated with Adr (2 μg/ml) or Etop (5 μM) for 4 hours. Endogenous p53 was successfully silenced by siRNA treatment, and
actin was shown as a loading control. (D) A ChIP assay showed that p53 bound to RKIP promoter. After treatment with the indicated
chemicals for 2 hours, A549 cells were sonicated and then incubated with anti-p53. Following extraction of p53-associated DNA, the pro-
moter regions were amplified using specific primers. p21 and DUSP14were used for positive controls, and GAPDH and DUSP5were shown
for negative controls. (E) Western blot analysis of A549 cells showed that RKIP was increased in the growth factor stimulation. Cells were
treated with IGF-1 (5 μg/ml) under serum-free condition for the indicated time. Actin was shown as a loading control. (F) SA-β-Gal staining of
A549 showed that IGF-1 induced cellular senescence. Cells were incubatedwith IGF-1 (5 μg/ml) for 24 hours under serum-free condition and
subjected to SA-β-Gal staining. (G) Western blot analysis of p53 isogenic cell lines showed that IGF-1 as well as Adr induced RKIP and DcR2
in HCT116 p53+/− cells. Cells were incubated with Adr (2 μg/ml) or IGF-1 (5 μg/ml) for 4 hours. Actin was shown as a loading control.
(H) Western blot analysis of p53 isogenic cell lines showed that oncogenic activation increased RKIP and DcR in HCT116 p53+/− cells.
Cells were transfected with H-RasG12V and DN-Ras for 24 hours. Actin was shown as a loading control.
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siRNA in A549 cells [27]. Elimination of RKIP could increase ERK
activation and suppress the cellular senescence (Figure 4, A and B).
Conversely, RKIP overexpression inhibited ERK activation and in-
duced the cellular senescence (monitored by SA-β-Gal and DcR2 ex-
pression) in two kinds of p53-deficient cell lines (HCT116 p53−/− cells
and PC3; human prostate cancer cell line; Figures 4, C–E , and
W3A). In contrast, suppression of Ras-Raf-ERK pathway using Raf
kinase inhibitor could induce the cellular senescence (Figure W3B).
These results suggested that elevated expression of RKIP itself is enough
for induction of senescence and it is mediated by suppression of the
Raf-MAPK pathway. To confirm this, we transfected the ERK ex-
pression vector and checked the senescence. Ectopic expression of
ERK retained ERK phosphorylation and suppressed RKIP-induced
cellular senescence (Figures 4, F and G , and W3, C and D). To get
more evidence about the physiological role of RKIP, we checked the
effect of RKIP on cell proliferation in several kinds of cell lines using
trypan blue staining and MTT assay. As we expected, overexpression
of RKIP could suppress the cell proliferation (Figure W4, A and
B), whereas RKIP knockdown could promote the cell proliferation
(Figure W4, A and C ). Considering these results, RKIP promotes
Figure 4. RKIP is essential for senescence. (A) Western blot analysis of A549 cells showed that treatment with Adr did not reduce p-ERK
in the absence of RKIP. Cells were transfected with Si-C or Si-RKIP for 8 hours, and p-ERK expression was measured following treatment
with Adr (2 μg/ml, 2 hours). Actin was shown as a loading control. (B) SA-β-Gal staining of A549 cells showed that Adr did not induce
cellular senescence in the absence of RKIP. After transfection with si-RKIP or Si-C for 8 hours, A549 cells were incubated with Adr (2 μg/ml)
for 24 hours. After washing and fixing, cells were stained with SA-β-Gal staining solution. (C) Western blot analysis of HCT116 p53−/− cells
showed that overexpression of RKIP decreased p-ERK. Cells were transfected with RKIP for 48 hours. Actin was shown as a loading control.
(D) SA-β-Gal staining of HCT116 p53−/− cells showed that overexpression of RKIP induced cellular senescence. Cells were transfected with
RKIP or empty vector (EV) vector for 48 hours. After washing and fixing, cells were stained with SA-β-Gal staining solution. (E) Immunostaining
of HCT116 p53−/− cells showed that RKIP overexpression increased DcR2. After transfection with RKIP for 48 hours, cells were fixed and
stainedwith anti-DcR2. Nucleuswas stainedwith DAPI. (F)Western blot analysis of HCT116 p53+/− andMKN45 cells showed that enhanced
ERK expression prevented the reduction of p-ERK by RKIP. Cells were transfected with RKIP alone or in combination with ERK for 24 hours.
Actin was shown as a loading control. (G) SA-β-Gal staining of HCT116 p53+/− and MKN45 cells showed that enhanced ERK expression
overcame the RKIP-mediated cellular senescence. Cells were transfected with RKIP alone or in combination with ERK for 24 hours. After
washing and fixing, cells were stained with SA-β-Gal staining solution.
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Figure 5. Phosphorylation of the p53 S46 residue is critical for RKIP induction and senescence. (A) Western blot analysis of A549 cells
showed that phosphorylation of S46 residue of p53 (p–p53 S46) was induced by treatment with Adr but not with Etop. Phosphorylation
of other serine residues (S20 and S392) was induced by treatment with Etop as well as Adr. Cells were incubated with Adr (2 μg/ml) or Etop
(5 μM) for 4 hours. Actin was shown as a loading control. (B) Western blot analysis of HCT116 p53−/− cells showed that S46D induced
RKIP and DcR2, while S46A did not. Cells were transfected with the indicated vectors for 24 hours. Actin was shown as a loading control.
(C) SA-β-Gal staining of HCT116 p53−/− cells showed that S46D promoted cellular senescence with or without Adr treatment. Cells were
transfected with the indicated vectors for 24 hours and treated with Adr (2 μg/ml) for another 24 hours. After washing and fixing, cells were
stained with SA-β-Gal staining solution. (D) Western blot analysis of HCT116 p53−/− cells showed that acetyl p53 was not relevant to RKIP
induction. Cells were transfected with the K302R and K382R for 24 hours. Actin was shown as a loading control. (E) Western blot analysis
of A549 cells showed that treatment of IGF-1 as well as Adr induced p–p53 S46 and RKIP. Cells were incubated with Adr (2 μg/ml) or IGF-1
(5 μg/ml) for the indicated time. Actin was shown as a loading control. (F) Western blot analysis of HCT116 p53−/− cells showed that the
elimination of RKIP abolished the effect of S46D on p-ERK and DcR2. Cells were transfected with S46D alone or in combination with siRNA
against RKIP for 24 hours. Actin was shown as a loading control. (G) Immunostaining of HCT116 p53−/− cells revealed that induction
of DcR2 by S46D was not shown in the absence of RKIP. Cells were transfected with S46D alone or in combination with siRNA against
RKIP for 24 hours. After transfection, cells were fixed and stained with anti-DcR2. Nucleus was stained with DAPI.
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cellular senescence and suppresses cell proliferation through inhibition
of ERK activity.
Modification of the S46 Residue of p53 Is Critical for RKIP
Induction and Senescence
Treatment with Adr but not Etop induced RKIP expression and
cellular senescence (Figure 2). Moreover, RKIP was a direct target of
p53 (Figure 3D). Thus, our next question is how p53 regulates RKIP
transcript. p53 function and stability are regulated by phosphorylation
of its serine/threonine residues, in response to DNA damage or other
cellular stresses, resulting in apoptosis, cell cycle arrest, and senescence
[43–46]. To clarify the differential outcomes, observed in response
to Adr or Etop treatment, we examined p53 modification, in par-
ticular phosphorylation. Interestingly, treatment of Adr but not Etop
induced the phosphorylation of p53 at S46 residue (Figures 5A and
W5A). To know that S46 modification is responsible for RKIP induc-
tion and senescence, we transfected the phospho-mimic (S46D) or
nonphosphorylated (S46A) p53 mutant vector into HCT116p53−/−
cells. The S46D p53 mutant, but not the S46A mutant, induced
RKIP and DcR2 expression (Figures 5B and W5B). In addition, we
could observe the increase of SA-β-Gal–positive cells in p53 S46D–
transfected cells, regardless of Adr treatment (Figure 5C). In contrast,
we did not find the relevance between p53 acetylation and RKIP induc-
tion (Figure 5D), although p53 acetylation during cellular senescence
has been proposed [25], and we did not check all kinds of acetyl p53.
We could also observe the induction of p-S46 p53 as well as RKIP by
treatment of IGF-1 (Figure 5E ). Moreover, overexpression of S46D
promoted cellular senescence in an RKIP-dependent manner (Figure 5,
F and G ). These results suggested that phosphorylation of the S46
residue of p53 would be required for RKIP-mediated senescence.
Discussion
Cellular senescence has emerged as a critical barrier against cancer
progression. Indeed, oncogenes such as H-RasG12V, K-RasG12D, or
B-RafV600E can induce cellular senescence in mouse models as well
as human cancers [7,9,19,47–49]. Thus, promoting the cellular senes-
cence would be useful for tumor suppression.
In this study, we found that the Raf kinase inhibitor RKIP serves as
an inducer of cellular senescence through suppression of the cellular
proliferation pathway. According to previous reports, RKIP is involved
in progression through the G2/M checkpoint [27] and tumor metas-
tasis [50–52]. In addition, RKIP expression is reduced in several types
of human cancers [53–58]. Here, we demonstrate that RKIP is a direct
target of p53 and is responsible for p53-induced cellular senescence.
Although p53 is a multifunctional tumor suppressor protein that is
involved in cell cycle suppression, apoptosis, inhibiting angiogenesis,
suppressing metastasis, and promoting senescence [8,12], it is not clear
how p53 activity is differentially regulated, in particular induction of
senescence. Regarding this, we suggest that p53 is differentially modi-
fied at posttranslation level and that phosphorylation of the S46 residue
is essential for inducing cellular senescence and RKIP expression (Fig-
ure 5). These results provide a basic clue for understanding how dif-
ferent triggers regulate p53, although we cannot yet suggest a detailed
mechanism for how senescence triggers selective modification of the
p53 S46 residue.
We have also shown that cells can discern the different kinds of
cellular stresses. In fact, Adr treatment, but not Etop treatment, can
induce senescence obviously. While we do not yet know the detailed
mechanism of this action, Adr can induce RKIP expression and S46
modification of p53 (Figures 3 and 5A). These results imply that there
is a kinase that can modify the p53 S46 residue in response to Adr-
mediated DNA damage. Concerning this, two S46-responsive kinases,
HIPK2 and DYRK, have been proposed [59–61]. However, both
kinases are believed to be involved in p53-mediated apoptosis. Thus,
there may be additional kinases that are more directly involved in
cellular senescence.
In our study, we also show the induction of RKIP in response to
IGF-1 and oncogenic Ras transfection (Figure 3, G and H ). In addi-
tion, consistently with previous reports that IGF-1– or oncogenic Ras-
induced cellular senescence has been proposed to be mediated by p53
[15,20], RKIP induction in response to growth factors or oncogenic
Ras is mediated by p53 (Figure 3, G and H ). Interestingly, despite
of weak induction of p53, the phosphorylation of the S46 residue of
p53 by IGF-1 treatment shows a similar level with Adr treatment con-
dition (Figure 5E). These results indicated that RKIP induction was
fully dependent on modification of the p53 S46 residue. We could
also obtain the similar results from the p53 mutant experiment. De-
spite of similar stability of p53 S46D and S46A mutants, they show
quite different effect on the induction of RKIP and senescence (Fig-
ure 5, B and C). These results explained why simple increases of p53
expression do not induce senescence, whereas modified p53 shows a
strong effect on cellular senescence [14,15]. During senescence in-
duction, either levels of S46-phosphorylated p53 or its mimetic were
more critical than the total intracellular amounts of p53.
On the basis of our results (Figure 5) and other’s reports, phosphor-
ylation of p53 S46 residue is critical for cellular senescence and apop-
tosis [59–61]. However, S46 residue is not conserved between murine
and human. In fact, we did not observe the induction of RKIP in
response to Adr in mouse embryonic fibroblast (Figure W5C ). These
facts imply that the human system may require more complicate
senescence regulation mechanism because of long life span. However,
how cellular senescence of mouse cells is regulated by p53 should be
investigated by further investigation.
According to a previous report, RKIP expression is reduced in human
gastric cancers [56,57]. Although the RKIP locus, 12q24, is not known
to be loss of heterozygosity (LOH) in human cancer, RKIP reduction
has been linked with genomic deletion [62]. This result suggests that
deletion of RKIP can be achieved through microdeletion. Moreover,
RKIP expression exhibits an inverse relationship with cancer grades
[57]. Higher expressed RKIP in non-neoplastic tissues is reduced to
undetectable level in malignant gastric cancer tissues. These results
suggest that RKIP is not just a metastasis suppressor but also a blocker
of tumor initiation. Taken together, our results indicated that RKIP,
a novel target of p53, is responsible for p53-mediated senescence.
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Figure W1. RKIP induction is a p53-dependent event. (A) Western blot analysis of p53 isogenic cell lines showed that p-ERK was re-
duced in response to Adr treatment by p53 transcriptional activity. After treatment with cyclohexamide for 2 hours, cells were incubated
with Adr (2 μg/ml) for another amount time as indicated. (B) Western blot analysis of MKN45 cells (human gastric cancer cell line; wild-
type p53 and wild-type K-Ras) showed that p-ERK was reduced after treatment with Adr (2 μg/ml) for the indicated amount of time. Actin
was shown as a loading control. (C) RT-PCR analysis of HCT116 p53 isogenic cell lines showed that transcripts of RKIP were increased
in HCT116 p53–positive cells (HCT116 p53+/− cells) by treatment with Adr (2 μg/ml) for the indicated amount of time. GAPDH was used
as the loading control. (D) RT-PCR analysis of HCT116 p53–deficient cells (HCT116 p53−/− cells) showed that wild-type p53 but not
mutant induced RKIP expression. Cells were transfected with wild-type p53 or mutant p53 for 24 hours and incubated with Adr for
2 hours. DUSP14 and p21 were used for a positive control, and GAPDH was shown as the loading control.
Figure W2. Promoter regions of RKIP, DUSP14, and DUSP5. The underlined regions indicate the location of the primers used in the ChIP
assay. p53 CBS of RKIP and DUSP14. Arrows indicated location of primers for ChIP assay. Detailed sequences of the promoter regions
and their gene ID were represented.
Figure W3. RKIP is critical for cellular senescence. (A) Overexpression of RKIP promoted senescence in PC3 (human prostate cancer cell
line; p53-null and mutant K-Ras). Western blot analysis showed the expression of ectopic RKIP, and SA-β-Gal staining revealed that RKIP
mediated cellular senescence in PC3, consistent with the result in HCT116 p53−/− cells. Cells were transfected with RKIP for 48 hours.
(B) SA-β-Gal staining of MKN45 showed that Raf kinase inhibitor 1 (10 μM) could induce senescence. Cells were incubated with Raf
kinase inhibitor 1 for 24 hours with or without other chemicals. After washing and fixing, cells were stained with SA-β-Gal staining
solution. (C) SA-β-Gal staining of A549 and MKN74 cells showed that ERK overexpression could suppress RKIP-induced senescence,
consistent with the results in HCT116 p53+/− and MKN45 cells. Cells were transfected with RKIP alone or in combination with ERK for
24 hours and stained with SA-β-Gal staining solution. (D) SA-β-Gal staining of HCT116 p53+/− cells showed that overexpression of ERK
could overcome the RKIP-induced senescence. In contrast, ERK alone did not show obvious effect on senescence. Cells were trans-
fected with RKIP or ERK alone or in combination with RKIP and ERK for 24 hours and stained with SA-β-Gal staining solution.
Figure W4. Overexpression of RKIP inhibits cell proliferation. (A) Trypan blue staining of several cancer cell lines revealed the effect of
RKIP on cell growth. Overexpression of RKIP suppressed cell proliferation, while knockdown of RKIP promoted it in A549, MKN45, PC3,
and HT-29 cells. After transfection with EV, RKIP, Si-C, or si-RKIP for 72 hours, cells were fixed and stained with trypan blue staining
solution. (B) and (C) MTT assay of several cancer cell lines showed the effect of RKIP on cell viability. Overexpression of RKIP decreased
cell viability, while knockdown of RKIP increased it in A549, MKN45, PC3, and HT-29 cells. After transfection with EV, RKIP, Si-C, or si-RKIP
for 72 hours, cells were incubated with MTT solution for 4 hours and absorbance at 540 nm was measured.
Figure W5. S46 residue is critical for RKIP expression. (A) Western blot analysis of A549 cells showed that Adr but not Etop induced S46
phosphorylation as well as RKIP. Cells were incubated with Adr or Etop in the indicated concentration for 2 hours. Actin was shown as a
loading control. (B) Western blot analysis of HCT116 p53−/− cells showed that S46D induced RKIP expression, whereas S46A did not.
Cells were transfected with the indicated vector for 24 hours and treated with 2 μg/ml of Adr for 2 hours. Actin was shown as a loading
control. (C) Western blot analysis of p53 wild-type MEF cells showed that RKIP were not increased in treatment with Adr. Cells were
incubated with Adr (2 μg/ml) or Etop (5 μM) for the indicated amount of time. p21 was used for a positive control, and actin was shown
as a loading control.
